SERPINB2 Antibody (monoclonal) (M08)
Mouse monoclonal antibody raised against a partial recombinant SERPINB2.
- 产品详情
- 实验流程
Application ![]()
| WB, IP, E |
---|---|
Primary Accession | P05120 |
Other Accession | BC012609 |
Reactivity | Human |
Host | mouse |
Clonality | monoclonal |
Isotype | IgG2b Kappa |
Clone Names | 3A9 |
Calculated MW | 46596 Da |
Gene ID | 5055 |
---|---|
Other Names | Plasminogen activator inhibitor 2, PAI-2, Monocyte Arg-serpin, Placental plasminogen activator inhibitor, Serpin B2, Urokinase inhibitor, SERPINB2, PAI2, PLANH2 |
Target/Specificity | SERPINB2 (AAH12609, 1 a.a. ~ 100 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. |
Dilution | WB~~1:500~1000 IP~~N/A E~~N/A |
Format | Clear, colorless solution in phosphate buffered saline, pH 7.2 . |
Storage | Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. |
Precautions | SERPINB2 Antibody (monoclonal) (M08) is for research use only and not for use in diagnostic or therapeutic procedures. |
For Research Use Only. Not For Use In Diagnostic Procedures.
Provided below are standard protocols that you may find useful for product applications.
REFERENCES
Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility hot-spot. Johnatty SE, et al. PLoS Genet, 2010 Jul 8. PMID 20628624.Variation at the NFATC2 Locus Increases the Risk of Thiazolinedinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study. Bailey SD, et al. Diabetes Care, 2010 Jul 13. PMID 20628086.Polymorphisms in innate immunity genes and risk of childhood leukemia. Han S, et al. Hum Immunol, 2010 Jul. PMID 20438785.Risk of meningioma and common variation in genes related to innate immunity. Rajaraman P, et al. Cancer Epidemiol Biomarkers Prev, 2010 May. PMID 20406964.Up-regulation of plasminogen activator inhibitor-2 is associated with high-risk HPV and grade of cervical lesion at baseline but does not predict outcomes of high-risk HPV infections or incident CIN. Syrj?nen S, et al. Am J Clin Pathol, 2009 Dec. PMID 19926580.

终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。
如有疑问,联系:0512-88856768 tech-china@abcepta.com.